Inhibition of cancer procoagulant

Details Inhibition of cancer procoagulant Inhibition of cancer procoagulant

1991-06-28

1993-06-29

Griffin, Ronald W.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 19, 530330, 530331, A61K 3702

Patent

active

052234860

ABSTRACT:
Peptidyl inhibitors, for example, peptidyl diazomethyl ketones and peptidyl methylsulfonium salts wherein the peptidyl moiety comprises two to ten amino acid residues inhibit cancer procoagulant, a cysteine proteinase, that is necessary for the viability of malignant cells. This invention provides for methods of cancer therapy and blood detoxification wherein these peptidyl inhibitors are used to destroy malignant cells.

REFERENCES:
patent: 4461833 (1984-07-01), Gordon
Leytus et al. (1984) Proc. Natl. Acad. Sci. USA 81:3699-3702.
Gordon et al. (1985) Blood 66:1261-1265.
Falanga et al. (1989) Thrombosis Res. 54:389-398.

Affiliated with

Also associated with

Rating

Inhibition of cancer procoagulant does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibition of cancer procoagulant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of cancer procoagulant will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1755394